Last updated: August 24, 2026
Capricor’s August 22, 2026 PDUFA target action date for deramiocel passed with no public FDA action and no company statement. Activist investor Kaos Capital demanded a board overhaul on August 21. Arbutus Biopharma launched a $230 million Dutch auction tender offer the same day.
This page collects the verified record behind the weekend of August 21 through 23, 2026: the Capricor chronology, the Xspray manufacturing rejection history, the congressional letter on Chinese trial data, the listing vehicle comparison, and a scorecard of which scheduled dates in the last week actually produced a decision.
What happened to Capricor’s August 22 PDUFA date?
The date passed without any public action from the FDA and without a statement from Capricor. As of the evening of Sunday, August 23, 2026, the company’s most recent press release remains its second quarter results dated August 13. No approval, no complete response letter, and no formal extension notice has been posted.
This matters because the extension everyone has been assuming was never an FDA commitment. It was a company characterization. On the August 13 earnings call, chief executive Linda Marbán said Capricor would amend the biologics license application with 24 month open label extension data plus upper limb analyses, and that the agency “has indicated it is willing to review this amendment and upon receipt to extend the PDUFA action date accordingly.” That language did not appear in the written release, the extension length was never disclosed, and the FDA has not confirmed it in any public forum.
So the position on Monday morning is genuinely open. The most likely explanation is administrative: the amendment was received, the clock reset, and no one is obliged to announce it. But an unannounced reset and an unannounced problem look identical from outside, which is precisely the difficulty.
Capricor deramiocel chronology
| Date | Event | Source type |
|---|---|---|
| March 10, 2026 | Capricor announces new PDUFA target action date of August 22, 2026 | Company release, SEC exhibit |
| July 29, 2026 | The Lancet publishes HOPE-3 data | Company release |
| July 30, 2026 | CTGTAC advisory committee votes 3 yes / 9 no on effectiveness in Duchenne cardiomyopathy; no benefit risk vote taken | Company release |
| August 13, 2026 | Q2 results: cash, equivalents and marketable securities $237.9 million at June 30; Q2 net loss approximately $40.7 million; BLA under active review | Company release |
| August 13, 2026 | On the earnings call only, CEO says FDA indicated willingness to extend on receipt of a BLA amendment; length undisclosed | Call remarks, not in written release |
| August 21, 2026 | Kaos Capital publishes an open letter demanding board changes | Investor release |
| August 22, 2026 | PDUFA target action date. No public FDA action. | Verified absence as of August 23 |
What the HOPE-3 numbers actually say
The trial’s primary endpoint, upper limb function measured by Performance of the Upper Limb version 2.0, hit at p=0.029. The cardiac secondary endpoint, left ventricular ejection fraction, was revised to p=0.09 from an initially reported p=0.04. The prespecified cardiomyopathy subgroup came in at p=0.02.
That revision is the number that drove the advisory committee. The application is for cardiomyopathy, and the cardiac endpoint across the full population no longer clears conventional significance. Any approval that eventually arrives is likely to carry a narrower label than the one proposed.
What is Kaos Capital demanding at Capricor?
Kaos Capital, describing itself as a significant and growing shareholder without disclosing a stake size, published a letter on August 21 demanding board engagement within five business days, a meeting within fifteen, two independent director nominees, an M&A and strategic alternatives committee chaired by a shareholder backed director, a formal cash preservation plan, and independent counsel on governance.
The framing is the part worth reading. “Conviction in a lead program is not a license for a Board to concentrate all of a public company’s capital, risk, and future in a single regulatory outcome,” the letter says. Kaos cites a cash decline of roughly $80.2 million from year end 2025 to the $237.9 million reported at June 30, and first half operating expenses of $79.7 million including $23.5 million of general and administrative expense, which it describes as roughly double the prior year. The $237.9 million figure is from Capricor’s own release. The decline and expense figures are as Kaos states them.
Capricor has paused its exosome programs pending regulatory clarity on deramiocel, which is the concentration Kaos is objecting to. A company with one asset, one indication, and one date has no way to absorb a date that produces nothing.
Why did the FDA reject Xspray’s Dasynoc for a third time?
Because of a factory Xspray does not own. The complete response letter issued August 19, 2026 cites manufacturing observations at contract manufacturer NerPharMa in Italy and asks for additional commercial scale batch data following earlier corrective actions. The agency raised no concerns about clinical data, bioequivalence, or stability.
Dasynoc is an amorphous form of dasatinib for chronic myeloid leukemia and acute lymphoblastic leukemia. It reaches comparable exposure at a 30 percent lower dose and, unlike standard dasatinib, works alongside the proton pump inhibitors these patients are commonly prescribed. None of that is in dispute. It has never been in dispute.
Xspray Dasynoc rejection history
| Date | FDA action | Stated basis | Clinical concerns raised |
|---|---|---|---|
| 2023 | Complete response letter | Dosing information | No |
| October 2025 | Complete response letter | Label comprehension plus GMP observations at contract manufacturer; company noted no observations were directed at the Dasynoc production line, but FDA paused all new approvals at the facility | No |
| August 19, 2026 | Complete response letter | Manufacturing observations at NerPharMa; request for additional commercial scale batch data | No |
Chief executive Blake Leitch put the position plainly: “the remaining uncertainty is now linked to NerPharMa sufficiently addressing the FDA’s observations.” NerPharMa says it has completed remediation and notified the agency. The FDA has not decided whether a reinspection is required. Xspray intends to resubmit before the end of 2026.
Note what is missing from that paragraph. There is no date. A company three rejections deep on a drug with no clinical questions cannot tell shareholders when the decision comes, because the decision depends on an inspector’s calendar at a third party site.
What are Moolenaar and Cline asking the FDA to do about Chinese trial data?
Representatives John Moolenaar, who chairs the House Select Committee on the Chinese Communist Party, and Ben Cline sent a letter to Acting FDA Commissioner Kyle Diamantas asking the agency to exclude clinical data generated in China from drug applications unless the FDA has inspected the trial site within the previous twelve months, and to publish a risk assessment of American drug development’s dependence on Chinese trial data.
The letter was reported on August 21 by Endpoints News as an exclusive and covered the same day by BioSpace. The two outlets describe the second request slightly differently, so it is worth treating the general shape of the ask as established and the precise wording as not yet confirmed from the document itself.
The three deaths cited
| Trial or sponsor | Patient | Date of death | Reported cause |
|---|---|---|---|
| HuidaGene HG302, CRISPR therapy | Boy with Duchenne muscular dystrophy | August 2025 | Acute respiratory distress syndrome |
| Shanghai Jiao Tong University, brain directed gene editing | Six year old girl with Snijders Blok-Campeau syndrome | May 2025 | Severe immune reaction, seven days after dosing |
| RiboX Therapeutics RXIM002, in vivo CAR therapy | Patient with systemic sclerosis | Disclosed August 2026 | Not specified in reporting |
All three were investigator initiated trials, the Chinese regulatory pathway that has supplied a large share of the assets American companies have been licensing. RiboX in particular already holds an FDA cleared investigational new drug application for RXIM002 in autoimmune cytopenias, granted on the strength of complete data from its Chinese investigator initiated trial.
Neither the FDA nor the Select Committee nor the affected companies commented at publication. A letter from two members of the House is not policy. But the twelve month inspection window is a specific and testable ask, and if the agency adopted it, a large fraction of the licensing pipeline that ran through 2025 and 2026 would need to be sourced again or run again.
Who is taking Werewolf Therapeutics public as Ambros?
Ambros Therapeutics will absorb Werewolf Therapeutics in an all stock reverse merger announced August 21, 2026, alongside a $150 million oversubscribed private placement co led by RA Capital Management and Janus Henderson Investors. The combined company will trade as AMBX on Nasdaq and close in the first quarter of 2027.
The other investors named are Aberdeen Investments, Adage Capital Partners, ADAR1 Capital Management, Affinity Asset Advisors, Arkin Bio Capital, Balyasny Asset Management, Enavate Sciences, SilverArc Capital, Sphera Healthcare, and Woodline Partners. Jay Hagan is chief executive. The company will be based in San Diego with runway into the first half of 2029.
The lead asset is neridronate, a bisphosphonate for complex regional pain syndrome type 1, an orphan condition the companies size at roughly 65,000 newly diagnosed American patients a year. It was developed by Abiogen Pharma and is approved in Italy. It carries FDA breakthrough therapy, fast track, and orphan drug designations, and the Phase 3 CRPS-RISE trial reads out in 2028.
What a Nasdaq listing costs in 2026
| Deal | Announced | New money | Legacy shareholders retain | Lead investor |
|---|---|---|---|---|
| Skye Bioscience plus Redx into Fibrx | August 14, 2026 | Approximately $125 million aggregate | Skye approximately 5.38% | Abingworth |
| Fulcrum into Slate Medicines | August 17, 2026 | $245 million private placement | Fulcrum approximately 5.0%, plus an estimated $270 million dividend | Frazier Life Sciences |
| Werewolf into Ambros | August 21, 2026 | $150 million private placement | Werewolf approximately 6.8% | RA Capital and Janus Henderson |
Three deals in eight days, and the price is remarkably consistent. A biotech whose science has stopped working keeps roughly five to seven percent of the company that takes over its listing. That is what a clean Nasdaq shell with cash and no litigation is worth right now, and it is a market clearing price, not a negotiation outcome.
Why is Arbutus buying back $230 million of stock?
Arbutus Biopharma announced on August 21 a modified Dutch auction tender offer to repurchase up to $230 million of its common shares at $5.00 to $5.75 apiece, commencing August 24 and expiring September 29, 2026, funded from cash on hand. The money comes from its March 2026 patent settlement with Moderna.
Chief executive Lindsay Androski framed it as returning “the financial proceeds from this win to the shareholders who have stood by our side during this long process.” The company reported $92.6 million in cash, equivalents and marketable securities at June 30, before the initial settlement payment landed in July. J.P. Morgan Securities is dealer manager.
Arbutus continues developing imdusiran and the oral PD-L1 inhibitor AB-101 in chronic hepatitis B, and continues supporting its exclusive licensee Genevant in enforcing lipid nanoparticle patents against Pfizer and BioNTech. So this is not a wind down. It is a deliberate decision that the marginal dollar is worth more to shareholders than to the pipeline, which is an unusual thing for a clinical stage biotech to say out loud.
What is Roche building in Oregon?
Genentech will invest approximately $750 million in a new facility on its 75 acre Hillsboro, Oregon campus to assemble injectable medicines and delivery devices, including prefilled syringes and autoinjectors. The site will employ 250 specialized manufacturing staff, take roughly 200 construction workers to build, and begin commercial operations in 2031.
Roche describes a United States footprint of 13 manufacturing sites, 15 research and development sites, and approximately 25,000 employees across 24 locations in eight states. The Hillsboro announcement follows completion of the Holly Springs, North Carolina site supporting metabolic medicines including obesity treatments.
Device fill finish is the exact capability that has generated rejections all month. ITM’s radiopharmaceutical was blocked on chemistry, manufacturing and controls and a third party facility inspection. Scholar Rock removed a fill finish plant from its application. Xspray has now been rejected three times over a contract manufacturer. Owning the assembly line is starting to look like a regulatory strategy rather than a supply chain one.
Which scheduled dates actually produced a decision last week?
Of the dated events on the calendar for the week of August 17, roughly half resolved. The rest either passed in silence, produced no announcement, or were never given a date to begin with. This is the pattern worth tracking, because valuation models treat a calendar date as a commitment and it is not one.
| Scheduled event | Date | Outcome |
|---|---|---|
| Capricor deramiocel PDUFA | August 22, 2026 | Passed, no public FDA action |
| Amylyx $500.2 million offering close | On or about August 21 | No closing announcement as of August 23 |
| Ultragenyx GENGLYCOS decision | August 19 | Accelerated approval granted |
| Regeneron Pasatru decision | August 19 | Approved |
| Xspray Dasynoc decision | August 19 | Third complete response letter; no new date set |
| Senate HELP hearing on the FDA nominee | Not scheduled | No date as of August 23 |
| INTerpath-001 full data | Upcoming congress, unnamed | No venue or date announced |
What else moved over the weekend?
Aurinia Pharmaceuticals settled its patent litigation with Teva over generic voclosporin. Teva may not launch a generic version of Lupkynis before December 7, 2036, against patents expiring in December 2037.
Boehringer Ingelheim placed a Phase 1 study of BI 3031185, an oral small molecule, on voluntary enrollment hold to evaluate a safety event. Neither the nature of the event nor the drug’s mechanism has been disclosed. The trial began in early July 2026 in Fukuoka, Japan, with a healthy male safety cohort and a pharmacokinetic interaction arm in healthy women taking Bayer’s Yaz. A separate Phase 1b study tested the molecule in borderline personality disorder and attention deficit hyperactivity disorder.
Novo Nordisk began enrolling OASIS 5 (NCT07770841), a Phase 3 placebo controlled trial of two lower maintenance doses of oral Wegovy in obesity and overweight. The doses have not been disclosed. Oral semaglutide carries a lower gross margin than the injectable, so a lower effective dose improves the economics as well as tolerability.
On prescriptions, IQVIA data cited by Citi analysts put the Wegovy pill above 176,000 weekly United States scripts, its highest weekly rate since the January launch and 35 percent of total Wegovy prescriptions, up from 33 percent. Lilly’s Foundayo fell to 36,620 from 38,928 after five consecutive weeks of growth. These are analyst compiled figures, not company reported ones.
Frequently asked questions
Did the FDA approve Capricor’s deramiocel?
No. As of August 23, 2026 there has been no public FDA action of any kind on the application. The August 22 target action date passed without an approval, a complete response letter, or a formal extension notice.
Was Capricor’s PDUFA date officially extended?
Not on the public record. Capricor’s chief executive said on the August 13 earnings call that the FDA indicated willingness to extend upon receiving a BLA amendment. The FDA has not confirmed this, the statement did not appear in the written release, and no extension length was given.
What is deramiocel?
A cell therapy derived from cardiosphere derived cells, under review for cardiomyopathy associated with Duchenne muscular dystrophy. Capricor is the sponsor.
What did the HOPE-3 trial show?
The upper limb primary endpoint reached p=0.029. The left ventricular ejection fraction secondary endpoint was revised to p=0.09 from an initially reported p=0.04. A prespecified cardiomyopathy subgroup reached p=0.02.
How did the advisory committee vote on deramiocel?
The Cellular, Tissue and Gene Therapies Advisory Committee voted 3 yes and 9 no on effectiveness in Duchenne cardiomyopathy on July 30, 2026. No benefit risk vote was taken.
Who is Kaos Capital?
An investor in Capricor that describes itself as a significant and growing shareholder. It has not disclosed the size of its stake. It published a letter on August 21, 2026 demanding board changes, a cash preservation plan, and a strategic alternatives committee.
How much cash does Capricor have?
$237.9 million in cash, cash equivalents and marketable securities at June 30, 2026, per the company’s second quarter release. Kaos Capital says that is a decline of roughly $80.2 million from year end 2025.
Why was Dasynoc rejected again?
Manufacturing. The August 19, 2026 complete response letter cites observations at contract manufacturer NerPharMa and asks for additional commercial scale batch data. No clinical, bioequivalence, or stability concerns were raised.
What is Dasynoc?
An amorphous formulation of dasatinib for chronic myeloid leukemia and acute lymphoblastic leukemia, developed by Xspray Pharma. It achieves comparable exposure at a 30 percent lower dose and can be taken with proton pump inhibitors.
What does the congressional letter on Chinese trial data ask for?
That the FDA exclude clinical data generated in China unless it has inspected the trial site within the previous twelve months, and that it publish a risk assessment of American drug development’s dependence on Chinese trial data.
Who is the acting FDA commissioner?
Kyle Diamantas, per reporting from Endpoints News, BioSpace and CBS. Heidi Overton was nominated as commissioner on August 19, 2026 and no Senate HELP confirmation hearing had been scheduled as of August 23.
What is neridronate?
A bisphosphonate for complex regional pain syndrome type 1, developed by Abiogen Pharma and approved in Italy. It is the lead asset of Ambros Therapeutics and holds FDA breakthrough therapy, fast track, and orphan drug designations. The Phase 3 CRPS-RISE trial reads out in 2028.
What is a modified Dutch auction tender offer?
A repurchase in which the company sets a price range, shareholders specify the price within that range at which they will sell, and the company then buys at the lowest price that clears the intended volume. Arbutus set a range of $5.00 to $5.75 for up to $230 million of stock.
Where is Genentech building its new facility?
On its existing 75 acre campus in Hillsboro, Oregon. The roughly $750 million site will assemble injectable medicines and delivery devices and begin commercial operations in 2031.
What is the next FDA decision to watch?
Ultragenyx UX111 for Sanfilippo type A on September 19, 2026, and Scholar Rock apitegromab on September 30. Both were previously complicated by manufacturing questions rather than clinical ones.
Sources
Primary sources
Capricor Therapeutics, “Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA,” March 10, 2026, and SEC exhibit EX-99.1 filed the same date. Capricor Therapeutics second quarter 2026 results, August 13, 2026. Capricor Therapeutics, “Provides Update on FDA Advisory Committee Meeting for Deramiocel,” July 30, 2026. Capricor Therapeutics press release index reviewed August 23, 2026, showing no release after August 13.
Kaos Capital, “Kaos Capital Calls on Capricor (NASDAQ: CAPR) Shareholders,” August 21, 2026, PR Newswire.
Xspray Pharma, “Xspray Pharma receives Complete Response Letter (CRL) from FDA for Dasynoc,” August 19, 2026, and “Xspray Pharma provides update on the FDA process for Dasynoc,” October 8, 2025.
Arbutus Biopharma, “Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified ‘Dutch Auction’ Tender Offer,” August 21, 2026, GlobeNewswire.
Roche, “Roche’s US subsidiary Genentech announces manufacturing expansion in the United States,” August 20, 2026.
Werewolf Therapeutics and Ambros Therapeutics joint release and Werewolf Form 8-K, August 21, 2026.
Aurinia Pharmaceuticals Form 8-K on the Teva settlement, August 2026.
ClinicalTrials.gov record NCT07770841 (OASIS 5).
Trade press and analyst sources
Fierce Pharma, “Xspray’s Dasynoc approval bid foiled again by FDA’s contract manufacturer concerns,” August 20, 2026. Fierce Pharma, “The Oral GLP-1 Tracker,” August 21, 2026, citing IQVIA data compiled by Citi. Fierce Pharma on the Aurinia and Teva settlement, August 20, 2026. Fierce Biotech, “Boehringer places phase 1 study of investigational drug on hold to examine ‘safety event,'” August 21, 2026. Endpoints News, “Two GOP lawmakers call on FDA to increase scrutiny of Chinese trial data following deaths,” August 21, 2026. BioSpace, “Lawmakers urge FDA to enact new China policies after 3 gene therapy deaths,” August 21, 2026. BioSpace, “Capricor investor calls for change as company awaits decision on Duchenne candidate,” August 21, 2026. BioSpace, “Novo Nordisk starts trialing lower maintenance doses of oral Wegovy,” August 21, 2026.
Share price references are exchange closing data for August 19 through 21, 2026.
Related coverage
Capricor is amending its deramiocel BLA ahead of the August 22 PDUFA, the August 17 analysis of the deferral and what the HOPE-3 Lancet data showed.
Amylyx priced an upsized $500.2 million offering as the FDA approved Ultragenyx and Regeneron rare disease drugs, including the full binary ledger tally for the week of August 17.
Why the FDA rejected ITM’s radiopharma therapy and stalled Scholar Rock’s SMA filing, the origin of the manufacturing veto framework this weekend extends.
PTC and Lilly just bought Sangamo for parts, on what distressed clearing prices reveal about gene therapy valuations.
CDMO companies and cell and gene therapy manufacturing in 2026, background on the contract manufacturing landscape behind these rejections.
